TIDMABZA

RNS Number : 2387P

Abzena PLC

15 November 2016

Abzena plc

Notice of half year results

Cambridge, UK, 15 November 2016 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will be publishing its half year results for the six months to 30 September 2016 on Wednesday, 30 November 2016.

A presentation for analysts will be held at 9.30am on 30 November 2016 at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ.

Enquiries:

 
 Abzena plc 
  John Burt, Chief Executive 
  Officer 
  Julian Smith, Chief Financial 
  Officer                          +44 1223 903498 
 
 Numis (Nominated Adviser and 
  Broker) 
  Clare Terlouw / Paul Gillam      +44 20 7260 1000 
 
 N+1 Singer (Joint Broker) 
  Aubrey Powell / Liz Yong         +44 20 7496 3000 
 
 Instinctif Partners               +44 20 7457 2020 
  Melanie-Toyne Sewell / Rozi       abzena@instinctif.com 
  Morris

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).

   -- Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic 
      proteins, and cell line development for manufacture. 
 
   -- Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant 
      proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies. 
 
   -- Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for 
      optimizing the therapeutic properties of biopharmaceuticals. 
 
   -- Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture 
      ADCs to GMP standards.

For more information, please see www.abzena.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORDMMMMZKGGVZM

(END) Dow Jones Newswires

November 15, 2016 07:42 ET (12:42 GMT)

Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Abzena Charts.
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Abzena Charts.